
|Videos|October 1, 2015
Can Biosimilars Reduce Specialty Spending?
Author(s)Davy James, Managing Editor
David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.
Advertisement
David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Early Recognition and Routine Discussion: Improving Outcomes in Tardive Dyskinesia
2
Do GLP-1 Receptor Agonists Increase the Risk of Smell and Taste Disturbances?
3
Meet the FDA’s Newly Approved OTC Sunscreen Ingredient: Bemotrizinol
4
Melatonin May Reduce Musculoskeletal Pain and Improve Sleep
5










































































































